Key facts
- iVeena’s last known valuation is $24.1M (Jul 2020).
- It has raised $8.9M; the latest was Grant ($2.0M) in Sep 2025.
- Notable investors include US National Science Foundation, National Institutes of Health, BoomStartup, Mountain Pacific Partners, National Eye Institute — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for iVeena
- ·The full record, as it builds
Funding rounds
No funding rounds for iVeena are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iVeena
Developer of a novel proprietary drug candidate designed to treat ophthalmic diseases. The company's drug candidate offers a cure for post-surgery cataract inflammation, macular degeneration, diabetic retinopathy, and glaucoma, and uses novel approaches, including delivery from the lens capsule, enabling doctors to treat corneal diseases and myopic conditions effectively.
- Sector
- Healthcare
- HQ
- Salt Lake City, UT, United States
- Founded
- 2006
- Employees
- 8
- Website
- iveenamed.com/
- Ownership
- Privately Held (backing)
iVeena doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iVeena shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iVeena in its N-PORT filings yet. We sweep new filings monthly.